首页 | 本学科首页   官方微博 | 高级检索  
检索        

广东省肇庆地区冠心病患者CYP2C19基因多态性差异性分布
引用本文:张小乐,蔡肇栩,谢丽妍,梁龙清.广东省肇庆地区冠心病患者CYP2C19基因多态性差异性分布[J].临床荟萃,2021,36(5):408-411.
作者姓名:张小乐  蔡肇栩  谢丽妍  梁龙清
作者单位:肇庆市第一人民医院CCU,广东肇庆526000;肇庆市第一人民医院药学部,广东肇庆526000;肇庆市第一人民医院特需诊疗中心,广东肇庆526000
基金项目:广东省医学科学技术研究基金——广东省肇庆地区人群中 PEAR1、GPⅢa PIA2、GP1BA 基因多态性与急性心肌梗死患者阿司匹林抗血小板功能及临床预后的相关性研究(B2020133)
摘    要:目的 探讨广东省肇庆地区冠心病(CHD)患者CYP2C19基因多态性分布,并比较不同性别和不同地区间CYP2C19基因多态性的分布,为CHD患者抗血小板治疗的个体化用药策略提供理论基础.方法 2019年6月-2020年11月诊断为CHD的501例患者均采用数字荧光分子杂交技术对CYP2C19*2、CYP2C19*3和C...

关 键 词:冠状动脉疾病  多态现象  遗传  血小板聚集抑制剂
收稿时间:2021-02-02

Differential distribution of CYP2C19 gene polymorphism in coronary heart disease patients in Zhaoqing,Guangdong Province
Zhang Xiaole,Cai Zhaoxu,Xie Liyan,Liang Longqing.Differential distribution of CYP2C19 gene polymorphism in coronary heart disease patients in Zhaoqing,Guangdong Province[J].Clinical Focus,2021,36(5):408-411.
Authors:Zhang Xiaole  Cai Zhaoxu  Xie Liyan  Liang Longqing
Institution:a. Department of CCU, the First People's Hopital of Zhaoqing, Zhaoqing 526000,Chinab. Department of Pharmacy, the First People's Hopital of Zhaoqing, Zhaoqing 526000,Chinac. Department of Special Medical Center, the First People's Hopital of Zhaoqing, Zhaoqing 526000,China
Abstract:Objective To investigate the distribution of CYP2C19 gene polymorphism in patients with coronary heart disease(CHD) in Zhaoqing, Guangdong Province, and to compare the distribution of CYP2C19 gene polymorphism in gender and that in other regions in Guangdong Province, so as to provide theoretical basis of individualized medication for antiplatelet therapy in CHD patients. Methods A total of 501 CHD patients from June 2019 to November 2020 were detected for CYP2C19 * 2, CYP2C19 * 3 and CYP2C19 * 17 gene polymorphisms by digital fluorescence molecular hybridization technology. Results In 501 CHD patients, the genotype proportion of CYP2C19*1*17, CYP2C19*1*1, CYP2C19*1*2, CYP2C19*1*3, CYP2C19*2*2 and CYP2C19*2*3 were 0.80%, 44.11%, 36.13%, 6.39%, 8.98% and 3.59%, respectively; the proportion of metabolic phenotypes of CYP2C19: ultrafast(UM), extensive(EM), intermediate(IM) and poor(PM) were 0.80%, 44.11%, 42.51% and 12.58%, respectively. The allele frequencies of CYP2C19*1,*2,*3 and *17 were 65.77%, 28.84%, 4.99% and 0.40%, respectively. There were no significant difference in the distribution of CYP2C19 genotypes, alleles and metabolisms in different genders (P>0.05); there were no significant difference in the distribution of CYP2C19 alleles and metabolisms among Zhaoqing, Guangzhou, Foshan, Dongguan, Meizhou Hakka, as well as Northern Guangdong (P>0.05). Conclusion CYP2C19 gene polymorphism exists in CHD patients in Zhaoqing area, and the proportion of CYP2C19 * 2 and CYP2C19 * 3 functional deletion alleles is relatively higher. It is suggested that CYP2C19 gene polymorphism should firstly be detected in CHD patients before clopidogrel antiplatelet therapy, so as to evaluate the resistance risk of clopidogrel and develop a reasonable individualized medication plan for patients.
Keywords:coronary disease  polymorphism  genetic  platelet aggregation inhibitors  
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《临床荟萃》浏览原始摘要信息
点击此处可从《临床荟萃》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号